Active Biotech Management
Management criteria checks 3/4
Active Biotech's CEO is Helen Tuvesson, appointed in Jul 2017, has a tenure of 7.42 years. total yearly compensation is SEK4.05M, comprised of 56% salary and 44% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth SEK43.17K. The average tenure of the management team and the board of directors is 7.4 years and 5.6 years respectively.
Key information
Helen Tuvesson
Chief executive officer
SEK 4.0m
Total compensation
| CEO salary percentage | 56.0% |
| CEO tenure | 7.4yrs |
| CEO ownership | 0.03% |
| Management average tenure | 7.4yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Jun 05
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?
Feb 19Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely
Jul 27Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
May 07Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation
Nov 09We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely
May 03We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate
Jan 18
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 42m |
| Jun 30 2024 | n/a | n/a | -SEK 44m |
| Mar 31 2024 | n/a | n/a | -SEK 45m |
| Dec 31 2023 | SEK 4m | SEK 2m | -SEK 46m |
| Sep 30 2023 | n/a | n/a | -SEK 48m |
| Jun 30 2023 | n/a | n/a | -SEK 51m |
| Mar 31 2023 | n/a | n/a | -SEK 54m |
| Dec 31 2022 | SEK 4m | SEK 2m | -SEK 58m |
| Sep 30 2022 | n/a | n/a | -SEK 60m |
| Jun 30 2022 | n/a | n/a | -SEK 57m |
| Mar 31 2022 | n/a | n/a | -SEK 56m |
| Dec 31 2021 | SEK 4m | SEK 2m | -SEK 50m |
| Sep 30 2021 | n/a | n/a | -SEK 38m |
| Jun 30 2021 | n/a | n/a | -SEK 35m |
| Mar 31 2021 | n/a | n/a | -SEK 32m |
| Dec 31 2020 | SEK 3m | SEK 2m | -SEK 32m |
| Sep 30 2020 | n/a | n/a | -SEK 39m |
| Jun 30 2020 | n/a | n/a | -SEK 40m |
| Mar 31 2020 | n/a | n/a | -SEK 36m |
| Dec 31 2019 | SEK 3m | SEK 2m | -SEK 34m |
| Sep 30 2019 | n/a | n/a | -SEK 32m |
| Jun 30 2019 | n/a | n/a | -SEK 31m |
| Mar 31 2019 | n/a | n/a | -SEK 35m |
| Dec 31 2018 | SEK 3m | SEK 1m | -SEK 37m |
| Sep 30 2018 | n/a | n/a | -SEK 88m |
| Jun 30 2018 | n/a | n/a | -SEK 88m |
| Mar 31 2018 | n/a | n/a | -SEK 103m |
| Dec 31 2017 | SEK 2m | SEK 1m | -SEK 109m |
Compensation vs Market: Helen's total compensation ($USD366.84K) is above average for companies of similar size in the Swedish market ($USD231.71K).
Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.
CEO
Helen Tuvesson (62 yo)
7.4yrs
Tenure
SEK 4,045,000
Compensation
Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 7.4yrs | SEK 4.05m | 0.031% SEK 43.2k | |
| Chief Financial Officer | 24.9yrs | no data | 0.023% SEK 32.1k | |
| Chief Medical Officer | 2.9yrs | no data | 0.011% SEK 15.7k |
7.4yrs
Average Tenure
62yo
Average Age
Experienced Management: ACTI's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 13.6yrs | SEK 206.00k | no data | |
| Independent Director | 5.6yrs | SEK 202.00k | 0.0017% SEK 2.4k | |
| Independent Chairman of the Board | 5.6yrs | SEK 524.00k | 0.049% SEK 67.2k | |
| Independent Director | 4.6yrs | SEK 203.00k | 0.044% SEK 60.4k | |
| Independent Director | 4.6yrs | SEK 207.00k | 0.015% SEK 21.3k |
5.6yrs
Average Tenure
64yo
Average Age
Experienced Board: ACTI's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Active Biotech AB (publ) is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Stefan Waldenlind | Carnegie Investment Bank AB |
| Thomas Bowers | Danske Bank |